©The Author(s) 2025.
World J Clin Oncol. Oct 24, 2025; 16(10): 110511
Published online Oct 24, 2025. doi: 10.5306/wjco.v16.i10.110511
Published online Oct 24, 2025. doi: 10.5306/wjco.v16.i10.110511
Figure 4 Subgroup analysis by immune checkpoint inhibitor regimen (monotherapy vs combination).
A-C: No significant difference was observed between the subgroups for (A) pathological complete response, (B) overall response rate and (C) resection rate. 95%CI: 95% confidence interval.
- Citation: Cicerone O, Oliviero B, Mantovani S, Maiocchi L, Ravetta V, Berton F, Corallo S, Vanoli A, Maestri M. Neoadjuvant immunotherapy in resectable hepatocellular carcinoma: A meta-analysis of the current evidence. World J Clin Oncol 2025; 16(10): 110511
- URL: https://www.wjgnet.com/2218-4333/full/v16/i10/110511.htm
- DOI: https://dx.doi.org/10.5306/wjco.v16.i10.110511